officially retracts the paper entitled, “miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1,” by Xingmei Li, Yuewen Li, Yuning Han, Bing Dong, Dan Liu, Liqun Che, Yu Liu, and Yuchun Wang (Cancer Biother Radiopharm. 2020;35(5):338–344; doi: 10.1089/cbr.2019.2983) due to the discovery that the paper was submitted from a paper mill. This is a violation of the journal's standard protocols and is considered an infraction against the rigorous standards of scientific publishing.
The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves, and does not tolerate any misconduct.
Get full access to this article
View all access options for this article.
References
1.
SchiffmanM.Cervical cancer screening: Epidemiology as the necessary but not sufficient basis of public health practice. Prev Med, 2017; 98:3.
2.
PimpleS, MishraG, ShastriS. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol, 2016; 28:4.
3.
Duenas-GonzalezA, CampbellS. Global strategies for the treatment of early-stage and advanced cervical cancer. Curr Opin Obstet Gynecol, 2016; 28:11.
4.
ZhuH, LuoH, ZhangW, et al.Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther, 2016; 10:1885.
5.
CollakFK, DemirU, SagirF. YAP1 Is Involved in Tumorigenic Properties of Prostate Cancer Cells. Pathol Oncol Res 2019. [Epub ahead of print]; DOI: 10.1007/s12253-019-00634.
6.
ZhangMY, LinJ, KuiYC. MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1. Eur Rev Med Pharmacol Sci, 2019; 23:2436.
7.
SunZ, OuC, LiuJ, et al.YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene, 2019; 38:2627.
8.
HeC, MaoD, HuaG, et al.The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med, 2015; 7:1426.
9.
LorenzettoE, BrencaM, BoeriM, et al.YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. Oncotarget, 2014; 5:2608.
10.
ZhangJ, ZhaoX, ZhangJ, et al.Circular RNA hsa_circ_0023404 exerts an oncogenic role in cervical cancer through regulating miR-136/TFCP2/YAP pathway. Biochem Biophys Res Commun, 2018; 501:428.
11.
YanY, ZhangD, LeiT, et al.MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2. Clin Exp Pharmacol Physiol, 2019; 46:928.
12.
CaoZ, XuL, Zhao S and ZhuX. The functions of microRNA-124 on bladder cancer. Onco Targets Ther, 2019; 12:3429.
13.
SunB, HuaJ, CuiH, et al.MicroRNA-1197 downregulation inhibits proliferation and migration in human non-small cell lung cancer cells by upregulating HOXC11. Biomed Pharmacother, 2019; 117:109041.
14.
PangH, YueX. MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting insulin-like growth factor receptor 1 in human cervical cancer. Tumour Biol, 2017; 39:1010428317701308.
15.
YueZ, Yun-ShanZ, Feng-XiaX. miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan. J Renin Angiotensin Aldosterone Syst, 2016; 17:1470320316663327.
16.
ZhangF, LiuJ, XieBB. Downregulation of microRNA-205 inhibits cell invasion and angiogenesis of cervical cancer through TSLC1-mediated Akt signaling pathway. J Cell Physiol, 2019; 234:18626.
17.
ZhouJ.An emerging role for Hippo-YAP signaling in cardiovascular development. J Biomed Res, 2014; 28:251.
18.
JerhammarF, JohanssonAC, CederR, et al.YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral Oncol, 2014; 50:832.
19.
SongS, HonjoS, JinJ, et al.The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res, 2015; 21:2580.
20.
ZhaoJ, LiX, YangY, et al.Effect of YAP1 silencing on esophageal cancer. Onco Targets Ther, 2016; 9:3137.
21.
YuL, GaoC, FengB, et al.Distinct prognostic values of YAP1 in gastric cancer. Tumour Biol, 2017; 39:1010428317695926.
22.
LuZ, XuY, YaoY, et al. miR-205-5p contributes to paclitaxel resistance and progression of endometrial cancer by downregulating FOXO1. Oncol Res 2019. [Epub ahead of print]; DOI: 10.3727/096504018X15452187888839.
23.
ZhuangL, GuoJ, YaoY, et al.miR-205 targets runt-related transcription factor 2 to inhibit human pancreatic cancer progression. Oncol Lett, 2019; 17:843.
24.
TaoY, SongY, HanT, et al.miR-205 regulation of ICT1 has an oncogenic potential via promoting the migration and invasion of gastric cancer cells. Biomed Pharmacother, 2017; 96:191.
25.
ZhaoW, WangH, HanX, et al.DeltaNp63alpha attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. Tumour Biol, 2016; 37:10621.
26.
WangQ, DingJ, NanG, et al.LncRNA NOC2L-4.1 functions as a tumor oncogene in cervical cancer progression by regulating the miR-630/YAP1 pathway. J Cell Biochem, 2019; 120:16913.
